TEROL LA (Detrol LA)2 mg – 30 tablet

$18.76

Each Terol La contains 2 mg Tolterodine 30 tablets a box, it is a treatment for an overactive bladder characterized by frequent urination.

ATC Classification: G04BD07
Active Ingrediant: Tolterodine Tartrate
Generic Name: TEROL LA
Manufacturer: Cipla Limited
Strength: 2 mg
Dosage Type: Capsule
Packaging Type: Foil
Contains: 30 Cap

Important update for customers in the USA:

Most of the World has stopped all packages mailing to the USA due to De Minimus Exemption.

  1. WE ARE SHIPPING TO THE USA The only or best option right now is trans shipment to the USA, we are holding India post and express mail shipments until India sets up a taxation / tariff collection system on our side which they say can take 1 month or longer.
  2. We ship normally to the UK, AUS, Japan, and most others. The situation only involves the USA.
  3. For people who have placed an order for express mail we will ship this out once India mail is open or you can contact us to make arrangements to ship through Trans Shipping and pay the tariff and shipping costs this way.
  4. We are very sorry for this, the USA policy shift came fast, without rules or regulations, and not understanding of what other countries should do.
  5. As things develop we will adjust our shipping prices and operations to best service you.
Thanks for your patience.
TEROL LA (Detrol LA)2 mg – 30 tablet
TEROL LA (Detrol LA)2 mg – 30 tablet
$18.76

Tolterodine Tartrate Information


Pronunciation

tole TER oh deen

 

What is this drug used for?

• It is used to treat an overactive bladder.

Frequently reported side effects of this drug

• Dizziness

• Fatigue

• Headache

• Abdominal pain

• Constipation

• Dry mouth

• Dry eyes

Other side effects of this drug: Talk with your doctor right away if you have any of these signs of:

• Unable to pass urine

• Vision changes

• Signs of a significant reaction like wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat.

 

Medication Safety Issues

Sound-alike/look-alike issues:

Tolterodine may be confused with fesoterodine, tolcapone

Detrol may be confused with Ditropan

Geriatric Patients: High-Risk Medication:

Beers Criteria: Tolterodine is identified in the Beers Criteria as a potentially inappropriate medication in patients 65 years and older due to its strong anticholinergic properties (Beers Criteria [AGS 2019]).

 

Storage and Stability

Store at 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). Protect from light.

 

Adverse Reactions

As reported with immediate release tablet, unless otherwise specified.

Cardiovascular: Chest pain

Central nervous system: Anxiety (extended release capsules), dizziness (immediate and extended release), drowsiness (immediate and extended release), fatigue (immediate and extended release), headache (immediate and extended release)

Dermatologic: Xeroderma

Endocrine & metabolic: Weight gain

Gastrointestinal: Abdominal pain (immediate and extended release), constipation (immediate and extended release), diarrhea, dyspepsia (immediate and extended release), xerostomia (more common with immediate release tablets)

Genitourinary: Dysuria (immediate and extended release)

Infection: Infection

Neuromuscular & skeletal: Arthralgia

Ophthalmic: Xerophthalmia (immediate and extended release), visual disturbance (immediate and extended release)

Respiratory: Bronchitis, flu-like symptoms, sinusitis (extended release)

Rare but important or life-threatening: Anaphylaxis, angioedema, confusion, dementia (aggravated), disorientation, hallucination, memory impairment, palpitations, peripheral edema, prolonged Q-T interval on ECG, tachycardia

Additional information

Active Ingrediant

Generic Name

Alternate Names

, , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,

Strength

Dosage Type

Packaging Type

Brand

Cipla

Reviews

There are no reviews yet.

Be the first to review “TEROL LA (Detrol LA)2 mg – 30 tablet”

Your email address will not be published. Required fields are marked *